Loading...
•
Sep 30, 2023
Generation Bio Q3 2023 Earnings Report
Generation Bio reported Q3 2023 financial results and business highlights.
Key Takeaways
Generation Bio reported a net loss of $28.3 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities were $291.0 million as of September 30, 2023, which is expected to fund operations into 2026. The company also highlighted advances in its iqDNA and ctLNP platforms.
Developed iqDNA to evade innate immune sensors, showing promising preclinical results in NHPs.
Demonstrated highly selective T cell transduction with its ctLNP delivery system in a humanized mouse model.
Cash balance of $291.0 million as of September 30, 2023, is expected to fund operations into 2026.
Advanced iqDNA as its lead cargo across all programs, including its lead program in hemophilia A.
Revenue by Segment
Forward Guidance
Generation Bio's cash position is expected to fund its operating plan into 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...